AZNAstraZenecaSigning up patients
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Lymphoma · Non-Hodgkin Lymphoma · Hodgkin Lymphoma · Peripheral T-cell Lymphoma (PTCL) · PTCL-NOS · ALCL · AITL
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 161 (planned)
- Started
- Jan 23, 2024
- Main results expected
- May 3, 2029
- Fully finished
- May 3, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: From Screening continuously until 28 days after the last dose of study medication.
Incidence of DLTs (Dose Escalation Cohorts only)
Measured over: From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06137144 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC